BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21670081)

  • 1. BMP4 promotes prostate tumor growth in bone through osteogenesis.
    Lee YC; Cheng CJ; Bilen MA; Lu JF; Satcher RL; Yu-Lee LY; Gallick GE; Maity SN; Lin SH
    Cancer Res; 2011 Aug; 71(15):5194-203. PubMed ID: 21670081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment.
    Lee YC; Gajdosik MS; Josic D; Clifton JG; Logothetis C; Yu-Lee LY; Gallick GE; Maity SN; Lin SH
    Mol Cell Proteomics; 2015 Mar; 14(3):471-83. PubMed ID: 25527621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.
    Karlou M; Lu JF; Wu G; Maity S; Tzelepi V; Navone NM; Hoang A; Logothetis CJ; Efstathiou E
    Prostate; 2012 Nov; 72(15):1638-47. PubMed ID: 22457212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer.
    Lin SC; Lee YC; Yu G; Cheng CJ; Zhou X; Chu K; Murshed M; Le NT; Baseler L; Abe JI; Fujiwara K; deCrombrugghe B; Logothetis CJ; Gallick GE; Yu-Lee LY; Maity SN; Lin SH
    Dev Cell; 2017 Jun; 41(5):467-480.e3. PubMed ID: 28586644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system.
    Chang AC; Chen PC; Lin YF; Su CM; Liu JF; Lin TH; Chuang SM; Tang CH
    Cancer Lett; 2018 Jul; 426():47-56. PubMed ID: 29627497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
    Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
    Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
    Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
    Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
    Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
    Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular patterning and permeability in prostate cancer models with differing osteogenic properties.
    Dafni H; Burghardt AJ; Majumdar S; Navone NM; Ronen SM
    NMR Biomed; 2012 Jun; 25(6):843-51. PubMed ID: 22134886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.
    Dai J; Hall CL; Escara-Wilke J; Mizokami A; Keller JM; Keller ET
    Cancer Res; 2008 Jul; 68(14):5785-94. PubMed ID: 18632632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
    Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
    Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.
    Straign DM; Ihle CL; Provera MD; Owens P
    Front Endocrinol (Lausanne); 2021; 12():769316. PubMed ID: 34956082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
    Pagel CN; Kularathna PK; Sanaei R; Young ND; Hooper JD; Mackie EJ
    Prostate; 2022 May; 82(6):723-739. PubMed ID: 35167724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
    Morrissey C; Lai JS; Brown LG; Wang YC; Roudier MP; Coleman IM; Gulati R; Vakar-Lopez F; True LD; Corey E; Nelson PS; Vessella RL
    Prostate; 2010 Mar; 70(4):412-24. PubMed ID: 19866469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.
    Wan X; Liu J; Lu JF; Tzelepi V; Yang J; Starbuck MW; Diao L; Wang J; Efstathiou E; Vazquez ES; Troncoso P; Maity SN; Navone NM
    Clin Cancer Res; 2012 Feb; 18(3):726-36. PubMed ID: 22298898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.
    Lee YC; Lin SC; Yu G; Cheng CJ; Liu B; Liu HC; Hawke DH; Parikh NU; Varkaris A; Corn P; Logothetis C; Satcher RL; Yu-Lee LY; Gallick GE; Lin SH
    Cancer Res; 2015 Nov; 75(22):4949-59. PubMed ID: 26530902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.